"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

NEW!!! I-SPY PATIENT INFORMATION SITE. Visit: www.ispypatient.org

Featured News

I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies I-SPY updates breast cancer subtypes with response-predictive biomarkers generated across 10 therapies

I-SPY in the News

June 14, 2022

Esserman brings urgency for ‘learning healthcare’ to learn faster, better Esserman brings urgency for ‘learning healthcare’ to learn faster, better

I-SPY in the News

June 6, 2022

Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting

I-SPY in the News

April 11, 2022

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.